KAIMRC researchers have unveiled how the so-called transmembrane receptor CD-95 governs the programmed death, or apoptosis, of lymphoma cells. This breakthrough is expected to give rise to novel ...
A new study published in the Journal for Immunotherapy of Cancer has presented a promising advancement in chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma (NHL).
“Beyond an important regulatory milestone, securing orphan drug designation for MB-105 from the FDA underscores the critical need for new therapeutic options for patients with T-cell lymphoma ...